139 related articles for article (PubMed ID: 22196956)
21. Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia.
Ruiz-Argüelles GJ; Ruiz-Delgado GJ; Ruiz-Reyes G; Chernoff SG
Mayo Clin Proc; 1998 Nov; 73(11):1125. PubMed ID: 9818051
[No Abstract] [Full Text] [Related]
22. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.
Furgerson JL; Vukelja SJ; Baker WJ; O'Rourke TJ
Am J Hematol; 1996 Feb; 51(2):137-40. PubMed ID: 8579054
[TBL] [Abstract][Full Text] [Related]
23. Leg ulcers and hydroxyurea: report of three cases with essential thrombocythemia.
Demirçay Z; Cömert A; Adigüzel C
Int J Dermatol; 2002 Dec; 41(12):872-4. PubMed ID: 12492973
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
Chaine B; Neonato MG; Girot R; Aractingi S
Arch Dermatol; 2001 Apr; 137(4):467-70. PubMed ID: 11295927
[TBL] [Abstract][Full Text] [Related]
25. [Multiple, painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea].
Martorell-Calatayud A; Requena C; Nagore-Enguídanos E; Guillén-Barona C
Actas Dermosifiliogr; 2009 Nov; 100(9):804-7. PubMed ID: 19889302
[TBL] [Abstract][Full Text] [Related]
26. A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
Dingli D; Tefferi A
Leuk Lymphoma; 2005 May; 46(5):641-50. PubMed ID: 16019501
[TBL] [Abstract][Full Text] [Related]
27. Essential thrombocythemia.
Finazzi G; Harrison C
Semin Hematol; 2005 Oct; 42(4):230-8. PubMed ID: 16210036
[TBL] [Abstract][Full Text] [Related]
28. Acral keratoses and leucocytoclastic vasculitis occurring during treatment of essential thrombocythaemia with hydroxyurea.
Worley B; Glassman SJ
Clin Exp Dermatol; 2016 Mar; 41(2):166-9. PubMed ID: 26269121
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
Kiladjian JJ; Besses C; Griesshammer M; Gugliotta L; Harrison C; Coll R; Smith J; Birgegård G
Clin Drug Investig; 2013 Jan; 33(1):55-63. PubMed ID: 23184668
[TBL] [Abstract][Full Text] [Related]
30. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Samuelson B; Chai-Adisaksopha C; Garcia D
J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476
[TBL] [Abstract][Full Text] [Related]
31. [Drug-induced fever caused by hydroxyurea. Apropos of 3 new cases].
Gallant C; Vial T; Allochon Y; Monier JM; Blanc M; Evreux JC
Ann Med Interne (Paris); 1998 Mar; 149(2):59-61. PubMed ID: 11490525
[TBL] [Abstract][Full Text] [Related]
32. Deliberate hydroxycarbamide overdose in an adult with essential thrombocythaemia.
Litt E; Thomas B; Smyth J; Desoysa L; Watson D
Br J Haematol; 2013 Oct; 163(2):280-1. PubMed ID: 23862669
[No Abstract] [Full Text] [Related]
33. Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma.
Antar A; Ishak RS; Otrock ZK; El-Majzoub N; Ghosn S; Mahfouz R; Taher AT
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):166-9. PubMed ID: 25467031
[TBL] [Abstract][Full Text] [Related]
34. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
Passamonti F; Cazzola M
Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447
[No Abstract] [Full Text] [Related]
35. Hydroxyurea therapy increases plasma erythropoietin in patients with essential thrombocythaemia or polycythaemia vera.
Johansson P; Andréasson B
Clin Lab Haematol; 2006 Aug; 28(4):233-6. PubMed ID: 16898960
[TBL] [Abstract][Full Text] [Related]
36. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
Radaelli F; Onida F; Rossi FG; Zilioli VR; Colombi M; Usardi P; Calori R; Zanella A
Hematology; 2008 Aug; 13(4):195-202. PubMed ID: 18796244
[TBL] [Abstract][Full Text] [Related]
37. Hydroxyurea and lower leg ulcers.
Nguyen TV; Margolis DJ
Cutis; 1993 Oct; 52(4):217-9. PubMed ID: 8261806
[TBL] [Abstract][Full Text] [Related]
38. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia.
Radaelli F; Colombi M; Calori R; Zilioli VR; Bramanti S; Iurlo A; Zanella A
Hematol Oncol; 2007 Sep; 25(3):115-20. PubMed ID: 17464935
[TBL] [Abstract][Full Text] [Related]
39. Anagrelide: a review of its use in the management of essential thrombocythaemia.
Wagstaff AJ; Keating GM
Drugs; 2006; 66(1):111-31. PubMed ID: 16398570
[TBL] [Abstract][Full Text] [Related]
40. Essential Thrombocythemia: The Dermatologic Point of View.
Cozzani E; Iurlo A; Merlo G; Cattaneo D; Burlando M; Pierri I; Gugliotta L; Parodi A
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):739-47. PubMed ID: 26432058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
